RCM Technologies, Inc. — Form 10-Q Summary
Business context and reporting period
The filing covers the 13 weeks ended March 30, 2024, compared with the 13 weeks ended April 1, 2023. This is the company’s fiscal 2024 first quarter; the request metadata’s “2023 Q1” does not match the filing period. RCM provides specialty healthcare staffing, engineering, life sciences and information technology services. Results are unaudited.
Key financial metrics
| Metric | Q1 2024 | Prior-year quarter |
|---|---|---|
| Revenue | $71.9 million | $67.1 million |
| Gross profit / margin | $20.4 million / 28.3% | $19.0 million / 28.3% |
| Operating income / margin | $5.8 million / 8.1% | $5.7 million / 8.5% |
| Net income | $4.0 million | $3.8 million |
| Diluted EPS | $0.48 | $0.41 |
| Operating cash flow | $6.4 million | $(0.8) million |
At March 30, 2024, cash was $2.1 million, current assets $89.8 million and current liabilities $62.8 million. Borrowings under the revolving credit facility were reported as $22.2 million in the balance sheet and debt note, with $21.1 million of additional availability; the facility is $45 million and matures April 24, 2026. The effective weighted-average borrowing rate, including unused line fees, was 6.8%. Total liabilities were $91.1 million and stockholders’ equity was $29.4 million.
Material changes versus the prior comparable period
- Revenue grew 7.2%, led by Engineering, up $5.0 million (27.1%). Specialty Health Care revenue declined $0.9 million (2.4%); Life Sciences and IT increased $0.7 million (7.9%).
- Gross margin was unchanged at 28.3%. Operating margin fell from 8.5% to 8.1%, while net income increased 3.0% and diluted EPS rose from $0.41 to $0.48. Lower weighted-average shares contributed to per-share growth.
- Operating cash flow improved by $7.3 million year over year. Investing used $0.7 million, mainly for property and equipment and continued ERP implementation. Financing used $9.7 million, including $8.6 million of net credit-line repayments. Cash declined $4.2 million during the quarter.
- Credit-line borrowings declined from $30.8 million at year-end to $22.2 million in the balance sheet and debt note. The filing’s MD&A separately states $20.2 million for March 30, an apparent inconsistency to verify.
Outlook, commentary, risks and unusual items
- Management says it believes liquidity is sufficient for at least the next 12 months and expects to remain in compliance with credit-facility covenants. No specific revenue, earnings or margin guidance is provided.
- Management describes demand as sensitive to economic conditions, client spending and competition. Risks include staffing and retention, customer concentration and collections, regulatory and labor costs, insurance claims, foreign exchange, cyber risk and litigation.
- Two customers each contributed more than 10% of quarterly revenue (21.7% and 12.4%); both were in Specialty Health Care. The segment’s non-school revenue fell, partly due to reduced services for a significant New York City rehabilitation client and lower COVID-related demand. School revenue increased.
- The company reported a continuing material weakness in internal control over financial reporting involving SAP/general-ledger segregation of duties and user-access controls. Management said this did not cause a misstatement; remediation is underway, including a planned 2024 SAP upgrade, but completion timing is uncertain.
- The company accrued $2.6 million for asserted claims. A disputed Industrial Processing project has a $0.5 million reserve; management cites a potential contractual damages limit of $3.3 million and insurance coverage, but gives no assurance that those limits or coverage will apply.
- The board authorized up to $50 million for share repurchases; no treasury shares were purchased in the quarter. The company also has a $50 million ATM program and reported no shares sold under it. It retired 44,567 shares associated with CEO equity awards.
- Management cites investments in sales and recruiting infrastructure and ongoing ERP work. Future contingent acquisition consideration was estimated at $2.0 million; actual payments may differ.
Important facts for investors to verify
- Confirm the reporting period: the filing is for Q1 2024, not Q1 2023.
- Reconcile the March 30 credit-line balance: $22.2 million in the financial statements and note versus $20.2 million in MD&A.
- Monitor customer concentration, Specialty Health Care demand and the sustainability of Engineering growth and margin improvements.
- Track cash conversion, receivables and deferred revenue, as well as borrowing availability and interest costs.
- Review remediation progress for the material weakness and developments in asserted claims, including the Industrial Processing matter.